Positive topline results were announced from the second pivotal phase 3 study evaluating daridorexant (Idorsia), an investigational dual orexin receptor antagonist, for the treatment of insomnia.
Heightened cognitive arousal at bedtime is linked to objective sleep disturbances and indicators of psychological hyperarousal at night and during the day.
Some behavioral sleep problems in early childhood are associated with the onset of mental health symptoms during early adolescence.
Among adults without a clinical diagnosis of ADHD, heavy alcohol use predicted more severe ADHD symptoms.
Nearly half of pregnant women suffer from poor quality sleep, particularly in the third trimester, and poor sleep is associated with an increased risk of preterm delivery and postnatal depression.
Dayvigo (lemborexant; Eisai) is now available for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.
More than one-third of medical staff members in hospitals during the COVID-19 outbreak in China reported insomnia symptoms.
Idorsia announced positive topline results from a phase 3 study of daridorexant, an investigational dual orexin receptor antagonist, for the treatment of insomnia.
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
As people around the world face prolonged periods of confinement to their homes during the COVID-19 pandemic, stress levels may disrupt sleep patterns and worsen overall mental health.
